346 related articles for article (PubMed ID: 31225409)
21. Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.
Pecorelli N; Licinio AW; Guarneri G; Aleotti F; Crippa S; Reni M; Falconi M; Balzano G
Front Oncol; 2021; 11():812102. PubMed ID: 35083158
[TBL] [Abstract][Full Text] [Related]
22. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going.
Coppola A; Farolfi T; La Vaccara V; Iannone I; Giovinazzo F; Panettieri E; Tarallo M; Cammarata R; Coppola R; Caputo D
J Clin Med; 2023 May; 12(11):. PubMed ID: 37297872
[TBL] [Abstract][Full Text] [Related]
25. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection.
Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada YU; Kumamoto T; Endo I
Anticancer Res; 2019 Aug; 39(8):4431-4440. PubMed ID: 31366541
[TBL] [Abstract][Full Text] [Related]
26. How A Patient with Resectable or Borderline Resectable Pancreatic Cancer should Be Treated-A Comprehensive Review.
Kwaśniewska D; Fudalej M; Nurzyński P; Badowska-Kozakiewicz A; Czerw A; Cipora E; Sygit K; Bandurska E; Deptała A
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686551
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
Front Oncol; 2020; 10():1112. PubMed ID: 32850319
[No Abstract] [Full Text] [Related]
28. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.
van Dam MA; Vuijk FA; Stibbe JA; Houvast RD; Luelmo SAC; Crobach S; Shahbazi Feshtali S; de Geus-Oei LF; Bonsing BA; Sier CFM; Kuppen PJK; Swijnenburg RJ; Windhorst AD; Burggraaf J; Vahrmeijer AL; Mieog JSD
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885196
[TBL] [Abstract][Full Text] [Related]
29. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
[TBL] [Abstract][Full Text] [Related]
30. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic ductal adenocarcinoma staging: A narrative review of radiologic techniques and advances.
Chu LC; Fishman EK
Int J Surg; 2023 Dec; ():. PubMed ID: 38085802
[TBL] [Abstract][Full Text] [Related]
32. Imaging preoperatively for pancreatic adenocarcinoma.
Pietryga JA; Morgan DE
J Gastrointest Oncol; 2015 Aug; 6(4):343-57. PubMed ID: 26261722
[TBL] [Abstract][Full Text] [Related]
33. Resection to Exploration Ratios and Associated Outcomes in Patients with Pancreatic Ductal Adenocarcinoma.
Malleo G; Casciani F; Lionetto G; Esposito A; Binco A; Solinas D; De Pastena M; Pea A; Paiella S; Salvia R
Ann Surg; 2024 Jan; ():. PubMed ID: 38214158
[TBL] [Abstract][Full Text] [Related]
34. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
35. A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy.
Cox RE; Mahipal A; Chakrabarti S
Cureus; 2021 Apr; 13(4):e14640. PubMed ID: 34055508
[TBL] [Abstract][Full Text] [Related]
36. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
[TBL] [Abstract][Full Text] [Related]
38. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
39. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.
Klaiber U; Leonhardt CS; Strobel O; Tjaden C; Hackert T; Neoptolemos JP
Langenbecks Arch Surg; 2018 Dec; 403(8):917-932. PubMed ID: 30397779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
